A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers
utilizing a slow-infusion intravenous (IV) route of administration. Standard safety,
pharmacokinetics (PK) and qEEG monitoring will be evaluated at all dose levels. Subsequently,
a 3-cohort multiple ascending dose (MAD) study will be conducted. Doses will be administered
on days 1, 4, 7, and 10. Standard safety parameters will be monitored, and PK will be
evaluated at all dose levels.